TY - JOUR
T1 - Radiolabeled somatostatin analogs in prostate cancer
AU - Thakur, Mathew L.
AU - Kolan, H.
AU - Li, J.
AU - Wiaderkiewicz, R.
AU - Pallela, V. R.
AU - Duggaraju, R.
AU - Schally, A. V.
N1 - Funding Information:
Work wus supported by American Cancer Society grant RD 377 and in part by DOE FG 02.92ER 61485. The authors extend their thanks to Ms. Kate Musselman for preparing the manuscript.
PY - 1997/1
Y1 - 1997/1
N2 - Vapreotide (RC-160), a somatostatin analog, was labeled with 99mTc by a direct method and also by using CPTA [1,4,8,11-tetraazacyclotetradecane] as a bifunctional chelating agent. The labeled compounds were evaluated in nude mice bearing experimental human prostate cancers. In these studies, 111InDTPA-D-Phe-Octreotide (111In-DTPA-octreotide) served as a standard and 99mTc-oxytocin as a receptor-non-specific control. 99mTc-octreotide was also used. The 24 h tumor uptake of 99mTc-RC-160 was nearly 400% higher, (p < 0.05), than that of 111In-DTPA-octreotide and diminished upon receptor blocking. In all tissues except the kidneys, the uptake of 99mTc-RC-160 was also higher than that of 111In-DTPA-octreotide. The uptake of 99mTc-RC-160 was influenced by the amount of peptide injected and the best tumor/muscle and tumor/blood ratios were obtained when only one μg of the peptide (200 Ci/mmol) was administered.
AB - Vapreotide (RC-160), a somatostatin analog, was labeled with 99mTc by a direct method and also by using CPTA [1,4,8,11-tetraazacyclotetradecane] as a bifunctional chelating agent. The labeled compounds were evaluated in nude mice bearing experimental human prostate cancers. In these studies, 111InDTPA-D-Phe-Octreotide (111In-DTPA-octreotide) served as a standard and 99mTc-oxytocin as a receptor-non-specific control. 99mTc-octreotide was also used. The 24 h tumor uptake of 99mTc-RC-160 was nearly 400% higher, (p < 0.05), than that of 111In-DTPA-octreotide and diminished upon receptor blocking. In all tissues except the kidneys, the uptake of 99mTc-RC-160 was also higher than that of 111In-DTPA-octreotide. The uptake of 99mTc-RC-160 was influenced by the amount of peptide injected and the best tumor/muscle and tumor/blood ratios were obtained when only one μg of the peptide (200 Ci/mmol) was administered.
KW - Tc labeled octreotide
KW - Tc labeled RC-160
KW - imaging prostate cancer
KW - radiolabeled somatostatin analogs
KW - receptor specific peptides in prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=0030975591&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030975591&partnerID=8YFLogxK
U2 - 10.1016/S0969-8051(96)00180-1
DO - 10.1016/S0969-8051(96)00180-1
M3 - Article
C2 - 9080482
AN - SCOPUS:0030975591
VL - 24
SP - 105
EP - 113
JO - International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology
JF - International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology
SN - 0969-8051
IS - 1
ER -
